Cite

HARVARD Citation

    Fumery, M. et al. (2021). Effectiveness and Safety of Ustekinumab Intensification at 90 mg Every 4 Weeks in Crohn's Disease: A Multicentre Study. Journal of Crohn's and colitis. pp. 222-227. [Online]. 
  
Back to record